Form 4: Vertex Pharma EVP Earns Performance Shares

Vertex Pharmaceuticals' EVP and CMO, Carmen Bozic, earned 11,333 performance shares, reflecting the attainment of performance-vesting requirements.

Summary

• Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc. (VRTX), earned a total of 11,333 shares of common stock.
• This includes 7,866 performance shares from a performance stock unit (PSU) award granted on February 1, 2023, with performance goals certified on January 22, 2026.
• An additional 3,467 performance shares were earned from a PSU award granted on February 12, 2025, with performance goals also certified on January 22, 2026.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• Following these reported transactions, Carmen Bozic beneficially owns 44,002 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The earning of performance shares by a key executive is a positive indicator, as it signifies the achievement of company performance goals. This aligns executive incentives with shareholder value creation.

Positives

• EVP and CMO Carmen Bozic earned 11,333 performance shares, indicating the company met specific performance-vesting requirements for these awards.
• The attainment of performance goals reflects positively on the company's operational and strategic execution, as certified by the management development and compensation committee.
• The transactions were conducted under a Rule 10b5-1(c) plan, demonstrating pre-planned and transparent insider trading practices.

Future Outlook

The earned performance shares will vest on February 13, 2026, and in installments beginning February 24, 2026, indicating future share distribution to the executive.

Industry Context

This filing reflects standard executive compensation practices within the pharmaceutical industry, where performance-based equity awards are common incentives to align management interests with shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive, as the achievement of performance goals by a key executive suggests strong company performance and alignment of management incentives with shareholder interests.
• Employees: May signal a positive internal environment where performance targets are being met.

Next Steps

• Vesting of 7,866 performance shares on February 13, 2026.
• Vesting of 3,467 performance shares in installments beginning February 24, 2026.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, Form 4, insider transaction, performance shares, stock award, executive compensation, Carmen Bozic, Rule 10b5-1